Cheryl A. Hawkes and Vivian Ng contributed equally to this work.
Small molecule inhibitors of Aβ-aggregation and neurotoxicity
Article first published online: 27 FEB 2009
© 2009 Wiley-Liss, Inc.
Drug Development Research
Special Issue: Alzheimer's Disease: A Light at the End of the Tunnel?
Volume 70, Issue 2, pages 111–124, March 2009
How to Cite
Hawkes, C. A., Ng, V. and McLaurin, J. (2009), Small molecule inhibitors of Aβ-aggregation and neurotoxicity. Drug Dev. Res., 70: 111–124. doi: 10.1002/ddr.20290
- Issue published online: 19 MAR 2009
- Article first published online: 27 FEB 2009
- Canadian Institutes for Health Research
- Natural Sciences and Engineering Research Council
- Alzheimer's Society of Canada
- Ontario Alzheimer's Society
- Alzheimer's disease
Alzheimer disease (AD) is characterized pathologically by extracellular amyloid deposits composed of Aβ peptide, neurofibrillary tangles (NFTs) made up of hyperphosphorylated tau, and a deficit of cholinergic neurons in the basal forebrain. Presently, only symptomatic therapies are available for the treatment of AD and these therapies have a limited time frame of utility. Amyloid disorders represent the effects of chronic Aβ production and are not a secondary pathological effect caused by a distant trigger; therefore targeting Aβ is a viable pursuit. In this review, we will discuss the various small molecule anti-aggregation inhibitors that have been reported in the literature, with emphasis on compounds that are presently being investigated in clinical trials. Drug Dev Res 70, 2009. © 2009 Wiley-Liss, Inc.